CytomX Therapeutics (CTMX) Net Income towards Common Stockholders (QoQ) (2014 - 2026)
CytomX Therapeutics (CTMX) Net Income towards Common Stockholders (QoQ) (2014 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
CytomX Therapeutics |
520.30 Mn |
173.59 Mn |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
31.17% |
| Dec 31, 2025 |
-86.31% |
| Sep 30, 2025 |
-9,139.61% |
| Jun 30, 2025 |
-100.65% |
| Mar 31, 2025 |
24.63% |
| Dec 31, 2024 |
229.08% |
| Sep 30, 2024 |
187.79% |
| Jun 30, 2024 |
-147.38% |
| Mar 31, 2024 |
1,547.67% |
| Dec 31, 2023 |
-72.03% |
| Sep 30, 2023 |
375.25% |
| Jun 30, 2023 |
67.17% |
| Mar 31, 2023 |
62.27% |
| Dec 31, 2022 |
69.81% |
| Sep 30, 2022 |
1.46% |
| Jun 30, 2022 |
7.77% |
| Mar 31, 2022 |
8.16% |
| Dec 31, 2021 |
-12.40% |
| Sep 30, 2021 |
-15.88% |
| Jun 30, 2021 |
-14.61% |
